Valsartan, a cornerstone angiotensin II receptor blocker (ARB), is a globally traded active pharmaceutical ingredient (API) and finished dosage drug. Originally developed and marketed by Novartis under the brand name Diovan, the drug is now widely available in generic formulations, driving a robust international trade ecosystem. The global Valsartan market was valued at US$ 631 million in 2024 and is projected to reach US$ 969 million by 2031, growing at a steady CAGR of 6.4%. For API manufacturers, generic drug exporters, and pharmaceutical supply chain professionals, identifying the right global buyers is essential for capitalizing on this expanding market. This article provides a curated overview of the Valsartan global buyers list, segmented by…